Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | FLT1 | P17948 | 4/20 | 1.00 |
| ▸ | FLT4 | P35916 | 4/20 | 1.00 |
| ▸ | BMP4 | P12644 | 4/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.70 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.70 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.70 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.70 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.70 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.70 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.64 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610618 | 0.88 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL7610653 | 0.86 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL7618989 | 0.85 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL3003967 | 0.84 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL13126019 | 0.83 | KDR (0.76) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL7616707 | 0.82 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL7616736 | 0.82 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL27218304 | 0.82 | KDR (1.00) | KDRFLT1FLT4BMP4BMPR1B | |
| SCHEMBL7610636 | 0.82 | KDR (1.00) | KDRFLT1FLT4BMP4ACVR1 | |
| SCHEMBL15996325 | 0.81 | KDR (0.76) | KDRFLT1FLT4BMP4BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | claimed |
| US-6235741-B1 | ANTICANCER AGENTS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-05-22 | — | — | US | claimed |
| EP-0984692-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-02-21 | — | — | EP | claimed |
| EP-0984692-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054093-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11318103-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-05-03 | — | — | US | disclosed |
| US-20190142758-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-05-16 | — | — | US | disclosed |
| US-10179111-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-19 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-6380203-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; TREATMENT OF TYROSINE KINASE-DEPENDENT DISEASES/CONDITIONS SUCH AS ANGIOGENESIS, CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY OR AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6235741-B1 | ANTICANCER AGENTS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0984692-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-0984692-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054093-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | ALK, ACVR2A, ACVR1 | KDR 46/4885FLT1 165/4885FLT4 192/4885 |
| US-10179111-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | KDR 203/4885FLT1 324/4885FLT4 542/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | KDR 260/4885FLT1 162/4885FLT4 129/4885 |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | KDR 203/4885FLT1 324/4885FLT4 542/4885 |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | KDR 138/4885FLT1 193/4885FLT4 203/4885 |
| US-11318103-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | KDR 203/4885FLT1 324/4885FLT4 542/4885 |
| US-20190142758-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | KDR 203/4885FLT1 324/4885FLT4 542/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885FLT1 118/4885FLT4 58/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | KDR 1564/4885FLT1 818/4885FLT4 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.